13 Jan New Dengue Vaccine Trial in Latin America Demonstrates Efficacy
MedicalResearch.com Interview with:
Gustavo Dayan, MD
Director, Clinical Development
Sanofi Pasteur Discovery Drive
Swiftwater, PA 18370
Medical Research: What is the background for this study? What are the main findings?
Dr. Dayan: This is the first dengue vaccine efficacy trial conducted in Latin America. The trial met its primary objective showing an efficacy of 60.8% against symptomatic VCD (virologically confirmed dengue) after a 3-dose vaccination schedule. Serotype-specific efficacy was also demonstrated against all four serotypes. Furthermore, the dengue vaccine candidate effectively reduced hospitalization due to dengue by 80.3% and severe dengue disease by 95.5% over the 25-month study period.
Medical Research: What should clinicians and patients take away from your report?
Dr. Dayan: These study findings are consistent with those reported from a second large-scale efficacy trial of the vaccine candidate conducted in Asia. Together, the documented efficacy of this dengue vaccine candidate shows that dengue can be prevented through vaccination.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Dayan: It is important to ensure that all 4 serotypes circulate during the trial to be able to show efficacy against disease caused by each serotype. For this reason a variety of settings should be included in the trials. The inclusion of several settings in 5 countries in different hemispheres was key to ensure circulation of the 4 serotypes and to assess efficacy against each serotype.
Citation:
N Engl J Med 2015; 372:113-123
January 8, 2015
DOI: 10.1056/NEJMoa1411037
[wysija_form id=”1″]
Last Updated on January 31, 2015 by Marie Benz MD FAAD